We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Noninvasive Biomarker Tests Could Eliminate Painful Liver Biopsies

By LabMedica International staff writers
Posted on 08 Sep 2023
Print article
Image: Noninvasive biomarker tests could be alternatives to painful liver biopsies (Photo courtesy of 123RF)
Image: Noninvasive biomarker tests could be alternatives to painful liver biopsies (Photo courtesy of 123RF)

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH, is a severe illness. Once the liver begins to scar, the risk of cirrhosis, liver cancer, and death significantly increases. Unfortunately, symptoms of MASH often do not appear until the disease reaches its advanced stages, typically when cirrhosis has developed. Currently, the sole method to diagnose MASH in patients is through liver biopsies. However, this approach offers insights from only a small portion of the liver and fails to provide an accurate overall assessment of the patient's condition. Liver biopsies are also painful, invasive, and expensive for patients. Despite some companies developing blood and imaging biomarker tests, none have met the stringent requirements for FDA regulatory approval. Now, a consortium dedicated to investigating noninvasive tests for liver disease has achieved a significant milestone by demonstrating the effectiveness of five such tests, moving closer to regulatory approval.

The research to evaluate blood and imaging biomarker tests for liver disease is part of NIMBLE – the Noninvasive Biomarkers of Metabolic Liver Disease project – was led by the Virginia Commonwealth University (VCU, Richmond, VA, USA). The NIMBLE biomarker tests were rigorously compared to established measures, including the FIB-4 index used to assess liver health. Any biomarker test that matched or exceeded the performance of existing lab tests was assessed for its potential use in diagnosing MASH and related conditions. Over 1,000 patients participated in this research. These five biomarker tests hold promise for diagnosing MASH and related conditions, providing a noninvasive alternative to liver biopsies. This development is expected to encourage patient participation in future clinical trials, which would otherwise necessitate invasive liver biopsies. Additionally, the use of noninvasive blood tests could significantly reduce the cost of conducting such studies, thus fostering greater interest in drug development. Equally important, these tests could be easily administered in a doctor's office.

“This brings us a step closer to having simple blood-based tests that can be ordered virtually in any clinical setting and will provide access to care to patients,” said Arun Sanyal, M.D., a professor at the VCU School of Medicine. “Such a step will facilitate our ability to identify those most at risk of outcomes and target them for therapy. It will also serve as a foundation for prognostic, disease monitoring and treatment-response biomarker development.”

Related Links:
VCU 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Human Placenta DNA
Human Placenta DNA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.